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to experience blood and marrow transplant nursing in a
controlled setting has allowed for smoother transitions into
the role of RN, allowing for shorter new nurse orientation,
low turnover rates and high retention rates.
The opportunity of working with experienced blood and
marrow transplant nurses provides new nurses with the
tools and support needed to be successful in a challenging
specialty.
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Fatigue is a highly prevalent symptom following hematopoi-
etic stem cell transplantation (HCT) that has been described as
intense and lasting for years following treatment. It is not
known why some HCT survivors continue to experience
persistent fatigue in the absence of cancer/cancer treatment
and how this fatigue compares to occasional tiredness found
in the general population. To gain an understanding of
persistent fatigue as a biobehavioral phenomenon, this pilot
study compared fatigue, physical activity, sleep, emotional
distress, cognitive functioning, and biologicalmeasures in HCT
survivors with persistent fatigue (n¼25) to matched healthy
controls (HC) with occasional tiredness (N¼25).
Methods, Intervention, & Analysis: This comparative,
descriptive study collected data using a multi-pronged
approach: (1) computerized real-time assessments of fatigue
over 7 days; (2) objective, real-time assessments of physical
activity and sleep over 7 days; (3) patient-reported fatigue
assessment using a psychometrically sound questionnaire
(Chalder Fatigue Scale) and computerized Adult Short Forms
of the PROMIS system (fatigue, sleep disturbances, and
emotional distress); (4) computerized objective testing of
cognitive functioning to assess sustained attention, memory
and executive function; and (5) biological measures (CBC/
Differential, CRP, TNF alpha, and IL-6). Descriptive statistics
were calculated for all measures. Differences between the HCT
survivors and HC were examined using MANOVA.
Findings & Interpretation: HCT survivors with persistent
fatigue reported increased physical (p < .001), mental (p
<.001), and overall fatigue (p < .001) as well as increased
anxiety (p < .05) and depression (p< .01) compared to the
matched HC group with occasional tiredness. These differ-
ences were clinically signiﬁcant. RBC levels were signiﬁ-
cantly lower in the HCT survivors although levels for both
groups were in the normal range. TNF alphawas signiﬁcantly
higher in the HCT survivors (p < .001).
Discussion & Implications: These ﬁndings provide pre-
liminary evidence for a biobehavioral model of persistent
fatigue in HCT survivors. Persistent fatigue reported by HCT
survivors is accompanied by increased anxiety and
depression along with decreased RBC levels. Elevated TNF
alpha levels may represent an important biomarker. The
role of physical activity, sleep, and cognitive functioning is
less clear. These ﬁndings may have important implications
for interventions designed to reduce fatigue in HCT survi-
vors.135
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Improvements in transfusion medicine, blood typing, and
donor screening have reduced the likelihood of a reaction
from administration of blood products. In an effort to prevent
transfusion reactions, our current standard is to administer
acetaminophen 650mg and diphenhydramine 25mg, 30
minutes before transfusions. This practice may unnecessarily
place patients at increased risk for complications including
falls, cognitive impairment, and hepatic toxicity.
Methods, Intervention, & Analysis: P¼Adult BMT/oncology
patient; I¼Does the prophylactic use of acetaminophen and
diphenhydramine; C¼versus no premedication;O¼affect the
incidence of blood transfusion reactions?
The evidence based practice committee (EBPC) at a
comprehensive cancer center in the Midwest conducted
a literature review to determine if evidence supported
the efﬁcacy for reducing transfusion reactions with
routine premedication utilizing acetaminophen and
diphenhydramine. The search strategy included elec-
tronic searches of numerous resources including PubMed
(MEDLINE), CINAHL (Cumulative Index to Nursing and
Allied Health Literature), Medline, Elton B. Stephens
Company (EBSCO), Ovid, and Scopus to gather estab-
lished information.
Findings & Interpretation: The results of one prospective,
randomized, double-blind, placebo-controlled and two
retrospective reviews were analyzed and failed to show any
beneﬁt to premedication prior to transfusion of blood
products. Based on the evidence, the EBPC sought to obtain a
baseline rate of transfusion reaction at their facility. Between
January and April 2014, a retrospective review was con-
ducted on 137 transfusion patients to determine the fre-
quency of transfusion-related reactions. Four transfusion
reactions were reported; all four patients had been pre-
medicated prior to transfusion. Six patients did not receive
any premedication; none of which had a transfusion-related
reaction.
Discussion & Implications: The chair of the EBPC presented
these ﬁndings at BMTQI. Committee concerns included the
possible increase in confounding febrile reactions that might
lead to unnecessary admissions and febrile transfusion re-
actionwork-ups. A compromisewas reached with the BMTQI
committee approving the elimination of Benadryl as a
routine premedication. Next steps will include imple-
mentation of this new protocol with additional data collec-
tion on rate of transfusion reactions for the next three
months. If results concur with reviewed evidence, this pro-
tocol changewill be expanded across the facility and can be a
platform for other centers who are still using premedication.
